K Number

Device Name

VIDAS TOXO IGG II (TXG) ASSAY MODEL 30 210

Manufacturer

BIOMERIEUX, INC.

Date Cleared

2000-05-22

(231 days)

Product Code

LGD

Regulation Number

866.3780

Intended Use

The VIDAS® TOXO IgG II (TXG) assay is intended for use with a VIDAS® (Vitek ImmunoDiagnostic Assay System) instrument as a quantitative automated enzyme-linked fluorescent immunoassay (ELFA) for the measurement of Toxoplasma gondii-specific IgG in human serum or plasma (EDTA, heparin). It is intended for use as an aid in determination of immune status. It is not intended for use in testing (screening) blood or plasma donors.

Device Description

The VIDAS TOXO IgG II (TXG) assay is an automated quantitative test that is performed in a VIDAS instrument. All assay steps and assay temperature are controlled by the VIDAS instrument. The assay principle combines a two step enzyme immunoassay sandwich method with a final fluorescent detection (ELFA). The Solid Phase Receptacle (SPR) serves as the solid phase as well as the pipetting device for the assay. Reagents for the assay are ready-to-use and pre-dispensed in the sealed reagent strips. All of the assay steps are performed automatically by the instrument. The VIDAS TXG kit contains 60 TXG Reagent Strips, 60 TXG SPRs, 1 bottle of calibrator, and 1 bottle each of Positive and Negative controls. Each VIDAS TXG assay requires one TXG Reagent Strip and one TXG SPR.

More Information

Contact

Type

Center

Panel

Date Received

Product Code

Subsequent Product Codes

Applicant Name (Manufacturer)

Device Name

Decision

Street 1

Street 2

City

State

Country Code

ZIP

Postal Code

Class Advise Committee

SSP Indicator

Third Party Reviewed

Expedited Review

Predicate Devices

Abbott IMx Toxo IgG 2.0 Antibody Assay

Reference Devices

Not Found

AI/ML (Artificial Intelligence / Machine Learning)

No
The description focuses on standard immunoassay technology and automated processes, with no mention of AI, ML, or related concepts.

Therapeutic

No
This device is an in vitro diagnostic (IVD) assay designed to measure Toxoplasma gondii-specific IgG in human samples to aid in determining immune status. It does not provide any therapy or treatment.

Diagnostic

Yes

The device aids in the determination of immune status by measuring Toxoplasma gondii-specific IgG, which is a diagnostic purpose.

SaMD (Software as a Medical Device)

The device description explicitly states that the assay is performed in a VIDAS instrument, which is a hardware component. The kit also includes physical components like reagent strips and SPRs. While the instrument controls the assay steps, the device is not solely software.

IVD (In Vitro Diagnostic)

Yes, this device is an IVD (In Vitro Diagnostic).

Here's why:

Intended Use: The intended use explicitly states it is for the "measurement of Toxoplasma gondii-specific IgG in human serum or plasma... It is intended for use as an aid in determination of immune status." This describes a test performed on samples taken from the human body to provide information about a person's health status.
Device Description: The description details a test kit with reagents and a system (VIDAS instrument) designed to perform an assay on biological samples (serum or plasma).
Performance Studies: The document includes performance data (sensitivity and specificity) comparing the device to a predicate device, which is typical for IVD submissions.

The definition of an In Vitro Diagnostic (IVD) is a medical device that is used to perform tests on samples such as blood, urine, or tissue, taken from the human body, to detect diseases, conditions, or infections. This device clearly fits that description.

PCCP (Predetermined Change Control Plan) Authorized

N/A

Overview

Intended Use / Indications for Use

Product codes

LGD

Device Description

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Not Found

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Nonclinical Testing:

Cross-reactivity/Interference: In two separate studies, a total of 85 samples from patients with a variety of disease states (and known anti-T. gondii IgG status) were tested in the VIDAS TXG assay. None of the samples tested yielded unexpected results.
Precision: Within-run precision calculations as described by NCCLS EP5-T2 yielded % CV ranging from 5.13 % to 7.21 % over the reportable range of the assay. Total precision calculations as described by NCCLS EPS-T2 yielded % CV ranging from 6.70 % to 11.52 % over the reportable range of the assay.
Linearity: Dilutions of 4 serum samples and the WHO standard were tested using the VIDAS TXG assay. Linear regression analysis of the results vielded correlation coefficients of 0.98 or greater.

Clinical Testing:

Sensitivity and Specificity (relative to predicate device): One thousand nine hundred forty serum samples were tested using the VIDAS TXG assay and the Abbott IMx Toxo IgG Antibody Assay. After retesting of initial VIDAS equivocal samples (as directed in the package insert), there were 30 VIDAS equivocal results and 19 Abbott equivocal results. For the remaining 1891 samples, the VIDAS TXG assay showed a relative sensitivity of 98.45% (95% confidence interval 97.06%-99.29%) and a relative specificity of 99.77% (95% confidence interval 99.33%-99.95%). These results support a determination of substantial equivalence.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Relative sensitivity of 98.45% (95% confidence interval 97.06%-99.29%).
Relative specificity of 99.77% (95% confidence interval 99.33%-99.95%).
Precision: % CV ranging from 5.13 % to 7.21 % (within-run); % CV ranging from 6.70 % to 11.52 % (total).
Linearity: Correlation coefficients of 0.98 or greater.

Predicate Device(s)

Abbott IMx Toxo IgG 2.0 Antibody Assay

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

Regulation Number and Section

§ 866.3780

Toxoplasma gondii serological reagents.(a)
Identification. Toxoplasma gondii serological reagents are devices that consist of antigens and antisera used in serological tests to identify antibodies toToxoplasma gondii in serum. Additionally, some of these reagents consist of antisera conjugated with a fluorescent dye (immunofluorescent reagents) used to identifyToxoplasma gondii from clinical specimens. The identification aids in the diagnosis of toxoplasmosis caused by the parasitic protozoanToxoplasma gondii and provides epidemiological information on this disease. Congenital toxoplasmosis is characterized by lesions of the central nervous system, which if undetected and untreated may lead to brain defects, blindness, and death of an unborn fetus. The disease is characterized in children by inflammation of the brain and spinal cord.(b)
Classification. Class II (performance standards).

Summary

Image /page/0/Picture/1 description: The image shows the logo for bioMerieux. The logo consists of a stylized globe above the company name. The globe is textured and appears to be made up of many small lines. The company name, "bioMerieux," is written in a sans-serif font, with the "b" and "M" in lowercase and the rest of the letters in uppercase.

K993319

510(k) SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

510(k) Number:

| Submitter: | bioMerieux, Inc.
1022 Hingham Street
Rockland, MA 02370
Phone (781) 871-4442
Fax (781) 871-3470
Contact Name: Anna J. DeMarinis |
|--------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|
| Date: | September 30, 1999 |
| Device Trade/Proprietary Name: | VIDAS TOXO IgG II (TXG) assay |
| Common or Usual Name: | Enzyme-linked Fluorescent Immunoassay (ELFA)
for the quantitative determination of Toxoplasma
gondii- specific IgG |
| Classification Name: | 21 CFR 866.3780, Toxoplasma gondii serological
reagents |
| Predicate Device: | Abbott IMx Toxo IgG 2.0 Antibody Assay |

Device Description:

Intended Use:

VIDAS® TOXO IgG II (TXG) is an automated quantitative test for use on a VIDAS® analyser for the quantitative measurement of anti- Toxoplasma gondii IgG in human serum or plasma (EDTA, heparin). It is intended for use as an aid in determination of immune status. It is not intended for use in testing (screening) blood or plasma donors.

Summary/Comparison of Technological Characteristics

The VIDAS TXG assay is substantially equivalent to the Abbott IMx Toxo IgG 2.0 Antibody Assay.

Maior similarities include:

1. Both are enzyme immunoassays which detect IgG antibodies to Toxoplasma gondii in human serum or plasma.
1. Both utilize 4-methylumbelliferyl phosphate substrate.

Major differences include:

1. The VIDAS TXG assay uses a Solid Phase Receptacle (SPR) to capture anti-T. gondii IgG. The IMx uses microparticles for capture.
1. The VIDAS TXG assay is a fully automated enzyme-linked fluorescent immunoassay (ELFA) which uses sealed reagent strips containing all reagents necessary for the assay. The IMx requires separate addition of reagents to the system.
1. The VIDAS TXG assay provides a factory created master curve which only requires running a single calibrator. The IMx requires running a set of calibrators.

Synopsis of Performance Testing

Nonclinical Testing:

1. Cross-reactivity/Interference: In two separate studies, a total of 85 samples from patients with a variety of disease states (and known anti-T. gondii IgG status) were tested in the VIDAS TXG assay. None of the samples tested yielded unexpected results.
1. Precision: Within-run precision calculations as described by NCCLS EP5-T2 yielded % CV ranging from 5.13 % to 7.21 % over the reportable range of the assay. Total precision calculations as described by NCCLS EPS-T2 yielded % CV ranging from 6.70 % to 11.52 % over the reportable range of the assay.
1. Linearity: Dilutions of 4 serum samples and the WHO standard were tested using the VIDAS TXG assay. Linear regression analysis of the results vielded correlation coefficients of 0.98 or greater.

Clinical Testing:

1. Sensitivity and Specificity (relative to predicate device): One thousand nine hundred forty serum samples were tested using the VIDAS TXG assay and the Abbott IMx Toxo IgG Antibody Assay. After retesting of initial VIDAS equivocal samples (as directed in the package insert), there were 30 VIDAS equivocal results and 19 Abbott equivocal results. For the remaining 1891 samples, the VIDAS TXG assay showed a relative sensitivity of 98.45% (95% confidence interval 97.06%-99.29%) and a relative specificity of 99.77% (95% confidence interval 99.33%-99.95%).
  These results support a determination of substantial equivalence. When the VIDAS TXG assay is used as instructed in the package insert, the above statements are true. The package insert should always be consulted along with a VIDAS Procedures Manual to ensure that the assay is being performed properly. For additional information, references are listed in the package insert.

Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three lines representing its body and head. The logo is surrounded by the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" in a circular arrangement.

MAY 2 2 2000

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Ms. Sandra L. Perreand Manager, Regulatory Affairs BioMérieux, Inc. 595 Anglum Drive Hazelwood, Missouri 63042

Re: K993319

Trade Name: VIDAS® TOXO IgG II (TXG) Assay Regulatory Class: II Product Code: LGD Dated: May 4, 2000 Received: May 11, 2000

Dear Ms. Perreand:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device. please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Steven Butman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

510(k) Number (if known):

Device Name: VIDAS TOXO IgG II (TXG) Assay

Indications for Use:

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Woody Dubois

510(k) Number

Prescription Use_y____________________________________________________________________________________________________________________________________________________________

Over-the-Counter Use _________________________________________________________________________________________________________________________________________________________